Works matching AU Frederich, Robert

Results: 36

Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 1, p. 40, doi. 10.1002/cpdd.454

By:

Wang, Ellen Q.;
Plotka, Anna;
Salageanu, Joanne;
Baltrukonis, Daniel;
Mridha, Khurshid;
Frederich, Robert;
Sullivan, Beth E.

Publication type:

Article

Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 583, doi. 10.1111/dom.16050

By:

Cosentino, Francesco;
Dagogo‐Jack, Samuel;
Frederich, Robert;
Cannon, Christopher P.;
Cherney, David Z. I.;
Mancuso, James P.;
Wynant, Willy;
Xing, Aiwen;
Gantz, Ira;
Cater, Nilo B.;
Pratley, Richard E.

Publication type:

Article

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 1, p. 215, doi. 10.1111/dom.16005

By:

Amin, Neeta B.;
Frederich, Robert;
Tsamandouras, Nikolaos;
Haggag, Amina Z.;
Schuster, Tilman;
Zmuda, Witold;
Palmer, Alexandra;
Vasas, Szilard;
Buckley, Gina;
Smith, Timothy R.;
DuBrava, Sarah J.;
Zhu, Qi;
Johnson, Margot

Publication type:

Article

Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3478, doi. 10.1111/dom.15687

By:

Odutayo, Ayodele;
Cosentino, Francesco;
Pratley, Richard E.;
Dagogo‐Jack, Samuel;
McGuire, Darren K.;
Frederich, Robert;
Fu, Wei;
Cannon, Christopher P.;
Cherney, David Z. I.

Publication type:

Article

Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965

By:

Kim, Joseph M.;
Bhatt, Deepak L.;
Dagogo‐Jack, Samuel;
Cherney, David Z. I.;
Cosentino, Francesco;
McGuire, Darren K.;
Pratley, Richard E.;
Liu, Chih‐Chin;
Cater, Nilo B.;
Frederich, Robert;
Mancuso, James P.;
Cannon, Christopher P.

Publication type:

Article

Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923

By:

Corbin, Karen D.;
Dagogo‐Jack, Samuel;
Cannon, Christopher P.;
Cherney, David Z.I.;
Cosentino, Francesco;
Frederich, Robert;
Liu, Jie;
Pong, Annpey;
Lin, Jianxin;
Cater, Nilo B.;
Pratley, Richard E.

Publication type:

Article

Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769

By:

Segar, Matthew W.;
Kolkailah, Ahmed A.;
Frederich, Robert;
Pong, Annpey;
Cannon, Christopher P.;
Cosentino, Francesco;
Dagogo‐Jack, Samuel;
McGuire, Darren K.;
Pratley, Richard E.;
Liu, Chih‐Chin;
Maldonado, Mario;
Liu, Jie;
Cater, Nilo B.;
Pandey, Ambarish;
Cherney, David Z. I.

Publication type:

Article

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1245, doi. 10.1111/dom.14691

By:

Dagogo‐Jack, Samuel;
Cannon, Christopher P.;
Cherney, David Z. I.;
Cosentino, Francesco;
Liu, Jie;
Pong, Annpey;
Gantz, Ira;
Frederich, Robert;
Mancuso, James P.;
Pratley, Richard E.

Publication type:

Article

The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1114, doi. 10.1111/dom.14677

By:

Cherney, David Z. I.;
Cosentino, Francesco;
Pratley, Richard E.;
Dagogo‐Jack, Samuel;
Frederich, Robert;
Maldonado, Mario;
Liu, Jie;
Pong, Annpey;
Liu, Chih‐Chin;
Cannon, Christopher P.

Publication type:

Article

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.

Published in:

BMC Endocrine Disorders, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1472-6823-14-17

By:

White, Judith L.;
Buchanan, Patricia;
Jia Li;
Frederich, Robert

Publication type:

Article

Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.

Published in:

European Heart Journal, 2023, v. 44, n. 48, p. 5163, doi. 10.1093/eurheartj/ehad639

By:

Pandey, Ambarish;
Kolkailah, Ahmed A;
Cosentino, Francesco;
Cannon, Christopher P;
Frederich, Robert C;
Cherney, David Z I;
Dagogo-Jack, Samuel;
Pratley, Richard E;
Cater, Nilo B;
Gantz, Ira;
Mancuso, James P;
McGuire, Darren K

Publication type:

Article

Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial.

Published in:

Diabetes Care, 2015, v. 38, n. 6, p. 1145, doi. 10.2337/dc14-2868

By:

Leiter, Lawrence A.;
Hwee Teoh;
Braunwald, Eugene;
Mosenzon, Ofri;
Cahn, Avivit;
Kumar, K. M. Prasanna;
Smahelova, Alena;
Hirshberg, Boaz;
Stahre, Christina;
Frederich, Robert;
Bonnici, Francois;
Scirica, Benjamin M.;
Bhatt, Deepak L.;
Raz, Itamar

Publication type:

Article

Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial.

Published in:

Diabetes Care, 2015, v. 38, n. 4, p. 696, doi. 10.2337/dc14-1850

By:

Udell, Jacob A.;
Bhatt, Deepak L.;
Braunwald, Eugene;
Cavender, Matthew A.;
Mosenzon, Ofri;
Steg, Ph. Gabriel;
Davidson, Jaime A.;
Nicolau, Jose C.;
Corbalan, Ramon;
Hirshberg, Boaz;
Frederich, Robert;
KyungAh Im;
Umez-Eronini, Amarachi A.;
He, Ping;
McGuire, Darren K.;
Leiter, Lawrence A.;
Raz, Itamar;
Scirica, Benjamin M.

Publication type:

Article

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial.

Published in:

Diabetology & Metabolic Syndrome, 2012, v. 4, n. 1, p. 36, doi. 10.1186/1758-5996-4-36

By:

Frederich, Robert;
McNeill, Robert;
Berglind, Niklas;
Fleming, Douglas;
Chen, Roland

Publication type:

Article

Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.

Published in:

Diabetes & Vascular Disease Research, 2011, v. 8, n. 2, p. 125, doi. 10.1177/1479164111404575

By:

Hollander, Priscilla L;
Jia Li;
Frederich, Robert;
Allen, Elsie;
Chen, Roland

Publication type:

Article

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ⩾ 65 years) with inadequately controlled type 2 diabetes mellitus.

Published in:

Clinical Interventions in Aging, 2013, v. 8, p. 419, doi. 10.2147/CIA.S41246

By:

Karyekar, Chetan S.;
Ravichandran, Shoba;
Allen, Elsie;
Fleming, Douglas;
Frederich, Robert

Publication type:

Article

Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity.

Published in:

Diabetes Therapy, 2023, v. 14, n. 2, p. 319, doi. 10.1007/s13300-022-01345-6

By:

Ji, Linong;
Liu, Jie;
Xu, Zhi Jin;
Wei, Zhiqi;
Zhang, Ruya;
Malkani, Seema;
Cater, Nilo B.;
Frederich, Robert

Publication type:

Article

Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV.

Published in:

Diabetes Therapy, 2021, v. 12, n. 5, p. 1279, doi. 10.1007/s13300-021-01033-x

By:

Budoff, Matthew J.;
Davis, Timothy M. E.;
Palmer, Alexandra G.;
Frederich, Robert;
Lawrence, David E.;
Liu, Jie;
Gantz, Ira;
Derosa, Giuseppe

Publication type:

Article

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.

Published in:

Diabetes Therapy, 2020, v. 11, n. 6, p. 1347, doi. 10.1007/s13300-020-00803-3

By:

Patel, Shrita;
Hickman, Anne;
Frederich, Robert;
Johnson, Susan;
Huyck, Susan;
Mancuso, James P.;
Gantz, Ira;
Terra, Steven G.

Publication type:

Article

Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].

Published in:

2022

By:

Cherney, David Z. I.;
Charbonnel, Bernard;
Cosentino, Francesco;
Dagogo-Jack, Samuel;
McGuire, Darren K.;
Pratley, Richard;
Shih, Weichung J.;
Frederich, Robert;
Maldonado, Mario;
Pong, Annpey;
Cannon, Christopher P.

Publication type:

Letter

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.

Published in:

Diabetologia, 2021, v. 64, n. 6, p. 1256, doi. 10.1007/s00125-021-05407-5

By:

Cherney, David Z. I.;
Charbonnel, Bernard;
Cosentino, Francesco;
Dagogo-Jack, Samuel;
McGuire, Darren K.;
Pratley, Richard;
Shih, Weichung J.;
Frederich, Robert;
Maldonado, Mario;
Pong, Annpey;
Cannon, Christopher P.

Publication type:

Article

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.

Published in:

Diabetologia, 2020, v. 63, n. 6, p. 1128, doi. 10.1007/s00125-020-05133-4

By:

Cherney, David Z. I.;
Heerspink, Hiddo J. L.;
Frederich, Robert;
Maldonado, Mario;
Liu, Jie;
Pong, Annpey;
Xu, Zhi J.;
Patel, Shrita;
Hickman, Anne;
Mancuso, James P.;
Gantz, Ira;
Terra, Steven G.

Publication type:

Article

Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial.

Published in:

American Journal of Nephrology, 2022, v. 53, n. 7, p. 516, doi. 10.1159/000524889

By:

Cherney, David Z.I.;
Cosentino, Francesco;
Dagogo-Jack, Samuel;
McGuire, Darren K.;
Pratley, Richard E.;
Frederich, Robert;
Maldonado, Mario;
Liu, Chih-Chin;
Pong, Annpey;
Cannon, Christopher P.

Publication type:

Article

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.

Published in:

Sleep & Breathing, 2023, v. 27, n. 2, p. 669, doi. 10.1007/s11325-022-02594-2

By:

Wojeck, Brian S.;
Inzucchi, Silvio E.;
Neeland, Ian J.;
Mancuso, James P.;
Frederich, Robert;
Masiukiewicz, Urszula;
Cater, Nilo B.;
McGuire, Darren K.;
Cannon, Christopher P.;
Yaggi, Henry Klar

Publication type:

Article

Severe leptin resistance in brown fat-deficient uncoupling protein promoter-driven diphtheria toxin A mice despite suppression of hypothalamic neuropeptide Y and circulating corticosterone concentrations.

Published in:

1998

By:

Mantzoros, Christos S.;
Frederich, Robert C.;
Qu, Daqing;
Lowell, Bradford B.;
Maratos-Flier, Eleftheria;
Flier, Jeffrey S.;
Mantzoros, C S;
Frederich, R C;
Qu, D;
Lowell, B B;
Maratos-Flier, E;
Flier, J S

Publication type:

journal article

Activation of β<sub>3</sub> Adrenergic Receptors Suppresses Leptin Expression and Mediates a Leptin-Independent Inhibition of Food Intake in Mice.

Published in:

Diabetes, 1996, v. 45, n. 7, p. 909, doi. 10.2337/diab.45.7.909

By:

Mantzoros, Christos S.;
Qu, Daqing;
Frederich, Robert C.;
Susulic, Vedrana S.;
Lowell, Bradford B.;
Maratos-Flier, Eleftheria;
Flier, Jeffrey S.

Publication type:

Article

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.

Published in:

Cardiovascular Diabetology, 2014, v. 13, n. 1, p. 2, doi. 10.1186/1475-2840-13-33

By:

Iqbal, Nayyar;
Parker, Artist;
Frederich, Robert;
Donovan, Mark;
Hirshberg, Boaz

Publication type:

Article

Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.

Published in:

2013

By:

Cook, William;
Bryzinski, Brian;
Slater, Jill;
Frederich, Robert;
Allen, Elsie

Publication type:

journal article

Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.

Published in:

European Journal of Heart Failure, 2025, v. 27, n. 3, p. 521, doi. 10.1002/ejhf.3511

By:

Pandey, Ambarish;
Kolkailah, Ahmed A.;
McGuire, Darren K.;
Frederich, Robert C.;
Cater, Nilo B.;
Cosentino, Francesco;
Pratley, Richard E.;
Dagogo‐Jack, Samuel;
Cherney, David Z.I.;
Wynant, Willy;
Gantz, Ira;
Mancuso, James P.;
Masiukiewicz, Urszula;
Cannon, Christopher P.

Publication type:

Article

796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-796-P

By:

CHERNEY, DAVID;
COSENTINO, FRANCESCO;
MCGUIRE, DARREN K.;
CHARBONNEL, BERNARD;
DAGOGO-JACK, SAMUEL;
PRATLEY, RICHARD E.;
SHIH, WEICHUNG J.;
MALDONADO, MARIO;
PONG, ANNPEY;
GANTZ, IRA;
FREDERICH, ROBERT;
MANCUSO, JAMES P.;
MASIUKIEWICZ, URSZULA;
CANNON, CHRISTOPHER P.

Publication type:

Article

786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-786-P

By:

DAGOGO-JACK, SAMUEL;
PRATLEY, RICHARD E.;
CHERNEY, DAVID;
CHARBONNEL, BERNARD;
MCGUIRE, DARREN K.;
COSENTINO, FRANCESCO;
SHIH, WEICHUNG J.;
LIU, JIE;
FREDERICH, ROBERT;
MANCUSO, JAMES P.;
RAJI, ANNASWAMY;
GANTZ, IRA

Publication type:

Article

785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-785-P

By:

DAGOGO-JACK, SAMUEL;
FREDERICH, ROBERT;
CHARBONNEL, BERNARD;
LIU, JIE;
CANNON, CHRISTOPHER P.;
SHI, HARRY;
MCGUIRE, DARREN K.;
CHERNEY, DAVID;
COSENTINO, FRANCESCO;
SHIH, WEICHUNG J.;
MASIUKIEWICZ, URSZULA;
GANTZ, IRA;
PRATLEY, RICHARD E.

Publication type:

Article

783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-783-P

By:

CHARBONNEL, BERNARD;
DAGOGO-JACK, SAMUEL;
CANNON, CHRISTOPHER P.;
CHERNEY, DAVID;
COSENTINO, FRANCESCO;
MCGUIRE, DARREN K.;
SHIH, WEICHUNG J.;
LIU, JIE;
PONG, ANNPEY;
GANTZ, IRA;
FREDERICH, ROBERT;
MANCUSO, JAMES P.;
PRATLEY, RICHARD E.

Publication type:

Article

1197-P: Two-Year Effects of Ertugliflozin on Renal Function.

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1197-P

By:

CHERNEY, DAVID;
HEERSPINK, HIDDO L.;
FREDERICH, ROBERT;
MALDONADO, MARIO;
PONG, ANNPEY;
XU, ZHI JIN;
LIU, JIE;
MANCUSO, JAMES P.;
GANTZ, IRA;
TERRA, STEVEN G.

Publication type:

Article

Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials.

Published in:

Clinical Cardiology, 2021, v. 44, n. 8, p. 1139, doi. 10.1002/clc.23665

By:

Cherney, David Z. I.;
Dagogo‐Jack, Samuel;
McGuire, Darren K.;
Cosentino, Francesco;
Pratley, Richard;
Shih, Weichung J.;
Frederich, Robert;
Maldonado, Mario;
Liu, Jie;
Wang, Shuai;
Cannon, Christopher P.

Publication type:

Article

Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.

Published in:

Journal of Clinical Endocrinology & Metabolism, 2023, v. 108, n. 8, p. 2042, doi. 10.1210/clinem/dgac764

By:

Dagogo-Jack, Samuel;
Frederich, Robert;
Jie Liu;
Cannon, Christopher P.;
Shi, Harry;
Cherney, David Z. I.;
Cosentino, Francesco;
Masiukiewicz, Urszula;
Gantz, Ira;
Pratley, Richard E.

Publication type:

Article